APRIL 30, 2021
Biophytis – Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareholders
Biophytis – Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareholders
Biophytis receives €980,000 DeepTech Funding from BPI France for the Development of Macuneos (BIO201) in Dry AMD
Biophytis – Convening of Another Combined General Meeting at a Later Date
Biophytis gives operational perspectives on its Sarconeos (BIO101) ahead of its upcoming AGM on April 26, 2021
Biophytis gives updates on its Phase 2-3 COVA study on COVID-19
Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis against Negma Group Ltd
Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) following Regulatory Authorities approvals in France and Belgium